LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article: A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort.

Ugarte-Gil, Manuel Francisco / Gamboa-Cardenas, Rocio Violeta / Reátegui-Sokolova, Cristina / Pimentel-Quiroz, Victor Román / Medina, Mariela / Elera-Fitzcarrald, Claudia / Rodriguez-Bellido, Zoila / Pastor-Asurza, Cesar Augusto / Perich-Campos, Risto Alfredo / Alarcón, Graciela S

Lupus science & medicine

2023 Volume 10, Issue 1

Abstract: Objective: To determine the possible predictive value of self-efficacy on health-related quality of life (HRQoL) in patients with SLE.: Methods: Patients with SLE from the Almenara Lupus Cohort were included. Self-efficacy was ascertained with the ... ...

Abstract	Objective: To determine the possible predictive value of self-efficacy on health-related quality of life (HRQoL) in patients with SLE. Methods: Patients with SLE from the Almenara Lupus Cohort were included. Self-efficacy was ascertained with the six domains from the Patient-Reported Outcomes Measurement Information System (PROMIS) self-efficacy for managing chronic conditions. For PROMIS domains, a score of 50 is the average for a clinical population (people with a chronic condition), a higher score indicates that the respondent has greater self-efficacy. HRQoL was ascertained with the physical and mental component summary (PCS and MCS) measures of the Short-Form 36 (SF-36). Generalised estimating equations were performed, using as outcome the PCS or MCS in the subsequent visit, and the self-efficacy domain in the previous visit; multivariable models were adjusted for possible confounders. The confounders were measured in the same visit as the self-efficacy domain. Results: Two-hundred and nine patients for a total of 564 visits were included; 194 (92.8%) patients were women and mean age at diagnosis was 36.4 (14.0) years. In the multivariable models, a better PCS was predicted by a better self-efficacy for managing symptoms, managing medications and treatments and managing social interactions and general self-efficacy; a better MCS was predicted by a better self-efficacy for managing daily activities, managing symptoms, managing medications and treatments and managing social interactions. Conclusion: A better self-efficacy is predictive of subsequent better HRQoL, even after adjustment for possible confounders. These results should encourage clinicians to develop strategies to improve self-efficacy in patients with SLE.
MeSH term(s)	Humans ; Female ; Adult ; Male ; Quality of Life ; Lupus Erythematosus, Systemic ; Self Efficacy ; Surveys and Questionnaires
Language	English
Publishing date	2023-02-14
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2779620-6
ISSN	2053-8790
ISSN	2053-8790
DOI	10.1136/lupus-2022-000874
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Unveiling the Link Between Antiphospholipid Antibodies and Cognitive Dysfunction in the Almenara Lupus Cohort.

Velarde-Mejía, Yelitza / Gamboa-Cárdenas, Rocío / Zevallos, Francisco / Medina, Mariela / Rodriguez-Bellido, Zoila / Pastor-Asurza, Cesar / Alarcón, Graciela S / Ugarte-Gil, Manuel F

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

2023 Volume 30, Issue 2, Page(s) 41–45

Abstract: Objective: Cognitive dysfunction is a prevalent manifestation of systemic lupus erythematosus (SLE). There is evidence for the role of antiphospholipid (aPL) antibodies on its etiopathogenesis. Our objective was to identify the association between aPL ... ...

Abstract	Objective: Cognitive dysfunction is a prevalent manifestation of systemic lupus erythematosus (SLE). There is evidence for the role of antiphospholipid (aPL) antibodies on its etiopathogenesis. Our objective was to identify the association between aPL antibodies and cognitive dysfunction in SLE patients. Methods: This cross-sectional study included 135 patients evaluated from March 2015 to October 2017 at one center. Cognitive deficit was measured using the NEUROPSI test. Disease activity and damage were ascertained using the SLEDAI-2K (SLE Disease Activity Index 2000) and the SDI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), respectively; aPL antibodies were measured by enzyme-linked immunosorbent assay. The association between cognitive dysfunction and aPL antibodies was evaluated using univariable and multivariable linear regression models adjusted for age, sex, education, socioeconomic status, disease duration, SLEDAI-2K, SDI, mean current dose of prednisone, time of exposure to glucocorticoids, and drug use (immunosuppressants, hydroxychloroquine, aspirin, and warfarin). Results: One hundred thirty-one patients (97.1%) were women; their mean (SD) age was 46.6 (12.5) years; 59 patients (43.7%) had positivity for at least 1 aPL antibody. IgM anticardiolipin (aCL) was positive in 24.5%, IgG in 13.5%, IgM aβ2GP1 in 16.8%, IgG anti-β2 glycoprotein in 24.6%, and the lupus anticoagulant in 5.3%. Ninety patients (66.7%) had some cognitive dysfunction. In the univariable analysis, a significant correlation between the NEUROPSI score and IgM aCL antibodies was found (B = -20.87 [SE, 3.2]; p < 0.001), which remained significant in the multivariable model (B = -13.89 [SE, 3.14]; p < 0.001). Conclusions: IgM aCL antibodies are associated with cognitive dysfunction in patients with SLE. Larger and longitudinal studies are needed to assess the impact of these findings.
MeSH term(s)	Humans ; Female ; Middle Aged ; Male ; Antibodies, Antiphospholipid ; Cross-Sectional Studies ; Lupus Erythematosus, Systemic/complications ; Antiphospholipid Syndrome/complications ; Antiphospholipid Syndrome/diagnosis ; Antiphospholipid Syndrome/epidemiology ; Antibodies, Anticardiolipin ; Cognitive Dysfunction/epidemiology ; Cognitive Dysfunction/etiology ; Immunoglobulin G ; Immunoglobulin M
Chemical Substances	Antibodies, Antiphospholipid ; Antibodies, Anticardiolipin ; Immunoglobulin G ; Immunoglobulin M
Language	English
Publishing date	2023-12-19
Publishing country	United States
Document type	Journal Article
ZDB-ID	1283266-2
ISSN	1536-7355 ; 1076-1608
ISSN (online)	1536-7355
ISSN	1076-1608
DOI	10.1097/RHU.0000000000002049
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4815: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.

Ugarte-Gil, Manuel Francisco / Gamboa-Cardenas, Rocio Violeta / Reátegui-Sokolova, Cristina / Pimentel-Quiroz, Victor Román / Medina, Mariela / Elera-Fitzcarrald, Claudia / Zevallos, Francisco / Pastor-Asurza, Cesar Augusto / Lofland, Jeniffer / Zazzetti, Federico / Karyekar, Chetan S / Alarcón, Graciela S / Perich-Campos, Risto Alfredo

Lupus science & medicine

2022 Volume 9, Issue 1

Abstract: Objective: To determine if achieving lupus low disease activity state (LLDAS) or remission prevents damage accrual in a primarily Mestizo population.: Methods: Patients with SLE from a single-centre cohort with at least two visits occurring every 6 ... ...

Abstract	Objective: To determine if achieving lupus low disease activity state (LLDAS) or remission prevents damage accrual in a primarily Mestizo population. Methods: Patients with SLE from a single-centre cohort with at least two visits occurring every 6 months were included. The definitions used were the following: for remission, the 2021 Definition Of Remission In SLE; and for LLDAS, the Asia Pacific Lupus Collaboration. Damage accrual was ascertained with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Univariable and three multivariable interval-censored survival regression models were done: (1) remission versus not on remission; (2) LLDAS/remission versus active; and (3) remission and LLDAS (not on remission) versus active. Three similar multivariable models were also examined considering the duration on each state. Possible confounders included in these analyses were gender, age at diagnosis, socioeconomic status, educational level, disease duration, antimalarial use and SDI at baseline. Results: Two hundred and eighty-one patients were included. Eighty-three patients (29.5%) showed increased SDI during the follow-up. In the analyses of remission, being on remission predicted a lower probability of damage (HR=0.456; 95% CI 0.256 to 0.826; p=0.010). In the analyses of LLDAS/remission, being on LLDAS/remission predicted a lower damage (HR=0.503; 95% CI 0.260 to 0.975; p=0.042). When both states were considered, remission but not LLDAS (not on remission) predicted a lower probability of damage (HR=0.423; 95% CI 0.212 to 0.846; p=0.015 and HR=0.878; 95% CI 0.369 to 2.087; p=0.768, respectively). When the duration of these states was taken into account, remission, LLDAS/remission and LLDAS not on remission were associated with a lower probability of damage accrual. Conclusions: LLDAS and/or remission were associated with a lower probability of damage accrual.
MeSH term(s)	Cohort Studies ; Humans ; Lupus Erythematosus, Discoid ; Lupus Erythematosus, Systemic/diagnosis ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/epidemiology ; Severity of Illness Index
Language	English
Publishing date	2022-02-22
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2779620-6
ISSN	2053-8790
ISSN	2053-8790
DOI	10.1136/lupus-2021-000616
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort.

Ugarte-Gil, Manuel Francisco / Gamboa-Cardenas, Rocio Violeta / Reátegui-Sokolova, Cristina / Pimentel-Quiroz, Victor Román / Medina, Mariela / Elera-Fitzcarrald, Claudia / Zevallos, Francisco / Pastor-Asurza, Cesar Augusto / Zazzetti, Federico / Karyekar, Chetan S / Alarcón, Graciela S / Perich-Campos, Risto Alfredo

Lupus science & medicine

2022 Volume 9, Issue 1

Abstract: Background: Flares in patients with SLE, regardless of their severity, have been associated with damage accrual. However, their impact on health-related quality of life (HRQoL) has not been fully evaluated. In fact, disease activity is only minimally ... ...

Abstract	Background: Flares in patients with SLE, regardless of their severity, have been associated with damage accrual. However, their impact on health-related quality of life (HRQoL) has not been fully evaluated. In fact, disease activity is only minimally associated with HRQoL. Objective: To determine the association between flares and HRQoL. Methods: Patients from the Almenara Lupus Cohort were included. Visits occurring between December 2015 and February 2020 were evaluated. Flares were defined as an increase on the SLE Disease Activity Index 2000 (SLEDAI-2K) of at least 4 points; severe flares were those with a final SLEDAI-2K ≥12 and mild-moderate flares all the others. HRQoL was measured using the LupusQoL. Univariable and multivariable generalised estimating regression equations were performed, adjusting for possible confounders. Confounders were determined at one visit, whereas the outcome was determined on the subsequent visit; flares were determined based on the variation of the SLEDAI-2K between these visits. Results: Two hundred and seventy-seven patients were included; 256 (92.4%) were female, mean age at diagnosis was 36.0 (SD: 13.3) years and mean disease duration at baseline was 9.1 (SD: 7.1) years. Patients had mean of 4.8 (SD: 1.9) visits and a mean follow-up of 2.7 (1.1) years. Out of 1098 visits, 115 (10.5%) flares were defined, 17 were severe and 98 mild-moderate. After adjustment for possible confounders, only severe flares were associated with a poorer HRQoL in planning, pain, emotional health and fatigue. Conclusions: Severe flares, but not mild-moderate, flares are associated with poorer HRQoL.
MeSH term(s)	Cohort Studies ; Fatigue/etiology ; Female ; Humans ; Lupus Erythematosus, Systemic/complications ; Male ; Quality of Life/psychology ; Severity of Illness Index
Language	English
Publishing date	2022-03-29
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2779620-6
ISSN	2053-8790
ISSN	2053-8790
DOI	10.1136/lupus-2021-000641
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.

Elera-Fitzcarrald, Claudia / Reatégui-Sokolova, Cristina / Gamboa-Cárdenas, Rocío V / Medina, Mariela / Zevallos, Francisco / Pimentel-Quiroz, Victor R / Cucho-Venegas, Jorge M / Alfaro-Lozano, José L / Rodriguez-Bellido, Zoila / Pastor-Asurza, Cesar A / Perich-Campos, Risto / Alarcón, Graciela S / Ugarte-Gil, Manuel F

Lupus

2022 Volume 31, Issue 1, Page(s) 105–109

Abstract: Objectives: This study aims to determine whether the MetS predicts damage accrual in SLE patients.: Methods: This longitudinal study was conducted in a cohort of consecutive SLE patients seen since 2012 at one single Peruvian institution. Patients ... ...

Abstract	Objectives: This study aims to determine whether the MetS predicts damage accrual in SLE patients. Methods: This longitudinal study was conducted in a cohort of consecutive SLE patients seen since 2012 at one single Peruvian institution. Patients had a baseline visit and then follow-up visits every 6 months. Patients with ≥ 2 visits were included. Evaluations included interview, medical records review, physical examination, and laboratory tests. Damage accrual was ascertained with the SLICC/ACR damage index (SDI) and disease activity with the SLEDAI-2K. Univariable and multivariable Cox-regression survival models were carried out to determine the risk of developing new damage. The multivariable model was adjusted for age at diagnosis; disease duration; socioeconomic status; SLEDAI; baseline SDI; the Charlson Comorbidity Index; daily dose; and time of exposure of prednisone (PDN), antimalarials, and immunosuppressive drugs. Results: Two hundred and forty-nine patients were evaluated; 232 of them were women (93.2%). Their mean (SD) age at diagnosis was 35.8 (13.1) years; nearly all patients were Mestizo. Disease duration was 7.4 (6.6) years. The SLEDAI-2K was 5.2 (4.3) and the SDI, 0.9 (1.3). One hundred and eight patients (43.4%) had MetS at baseline. During follow-up, 116 (46.6%) patients accrued at least one new point in the SDI damage index. In multivariable analyses, the presence of MetS was a predictor of the development of new damage (HR: 1.54 (1.05-2.26); Conclusions: The presence of MetS predicts the development of new damage in SLE patients, despite other well-known risk factors for such occurrence.
MeSH term(s)	Disease Progression ; Female ; Humans ; Longitudinal Studies ; Lupus Erythematosus, Discoid ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/drug therapy ; Metabolic Syndrome/epidemiology ; Severity of Illness Index
Language	English
Publishing date	2022-01-06
Publishing country	England
Document type	Journal Article
ZDB-ID	1154407-7
ISSN	1477-0962 ; 0961-2033
ISSN (online)	1477-0962
ISSN	0961-2033
DOI	10.1177/09612033211061481
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3717: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Relationship between care model and disease activity states and health-related quality of life in systemic lupus erythematosus patients.

Perea-Seoane, Luciana / Agapito-Vera, Estefania / Gamboa-Cardenas, Rocío V / Guzmán-Sánchez, Geny / Pimentel-Quiroz, Victor Román / Reategui-Sokolova, Cristina / Medina, Mariela / Elera-Fitzcarrald, Claudia / Noriega, Erika / Rodriguez-Bellido, Zoila / Pastor-Asurza, Cesar / Perich-Campos, Risto / Alarcón, Graciela S / Ugarte-Gil, Manuel F

Lupus

2021 Volume 31, Issue 1, Page(s) 110–115

Abstract: Objective: To assess whether the care model (comprehensive vs regular) has any impact on the clinical outcomes of systemic lupus erythematosus patients.: Methods: Between August 2019 and January 2020, we evaluated SLE patients being cared for at two ... ...

Abstract	Objective: To assess whether the care model (comprehensive vs regular) has any impact on the clinical outcomes of systemic lupus erythematosus patients. Methods: Between August 2019 and January 2020, we evaluated SLE patients being cared for at two Peruvian hospitals to define the impact of care model on disease activity state and health-related quality of life (HRQoL). Disease activity was ascertained with the SLEDAI-2K and the Physician Global Assessment (PGA) which allows to define Lupus Low Disease Activity State (LLDAS) and Remission. HRQoL was measured with the LupusQoL. The association between care model and disease activity (Remission and LLDAS) state was examined using a binary logistic regression model. The association with HRQoL was examined with a linear regression model. All multivariable analyses were adjusted for possible confounders. Results: 266 SLE patients were included, 227 from the comprehensive care model and 39 from the regular care model. The regular care model was associated with a lower probability of achieving remission (OR 0.381; CI: 95% 0.163-0.887) and LLDAS (OR 0.363; CI: 95% 0.157-0.835). Regular care was associated with a better HRQoL in two domains (pain and emotional health). We found no association between the care model and the other HRQoL domains. Conclusion: A comprehensive care model was associated with the probability of achieving remission and LLDAS but had no apparent impact on the patients' HRQoL.
MeSH term(s)	Humans ; Linear Models ; Lupus Erythematosus, Systemic/therapy ; Quality of Life ; Severity of Illness Index
Language	English
Publishing date	2021-12-30
Publishing country	England
Document type	Journal Article
ZDB-ID	1154407-7
ISSN	1477-0962 ; 0961-2033
ISSN (online)	1477-0962
ISSN	0961-2033
DOI	10.1177/09612033211063798
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3717: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Health-Related Quality of Life and fatigue are associated with a higher work productivity impairment in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.

Reategui-Sokolova, Cristina / Gamboa-Cárdenas, Rocío Violeta / Medina, Mariela / Zevallos-Miranda, Francisco / Zeña-Huancas, Paola Alejandra / Elera-Fitzcarrald, Claudia / Pimentel-Quiroz, Victor / Alfaro-Lozano, Jose / Pastor-Asurza, Cesar / Perich-Campos, Risto / Rodriguez-Bellido, Zoila / Alarcon, Graciela S / Ugarte-Gil, Manuel F

Lupus

2021 Volume 30, Issue 13, Page(s) 2157–2161

Abstract: Objectives: ...

Abstract	Objectives:
MeSH term(s)	Cross-Sectional Studies ; Efficiency ; Fatigue/epidemiology ; Fatigue/etiology ; Female ; Humans ; Lupus Erythematosus, Discoid ; Lupus Erythematosus, Systemic/complications ; Pain ; Quality of Life ; Severity of Illness Index ; Surveys and Questionnaires
Language	English
Publishing date	2021-11-21
Publishing country	England
Document type	Journal Article
ZDB-ID	1154407-7
ISSN	1477-0962 ; 0961-2033
ISSN (online)	1477-0962
ISSN	0961-2033
DOI	10.1177/09612033211052485
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3717: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Serum uric acid is associated with damage in patients with systemic lupus erythematosus.

Elera-Fitzcarrald, Claudia / Reátegui-Sokolova, Cristina / Gamboa-Cardenas, Rocio Violeta / Medina, Mariela / Zevallos, Francisco / Pimentel-Quiroz, Victor Román / Cucho-Venegas, Jorge Mariano / Alfaro-Lozano, José / Rodriguez-Bellido, Zoila / Pastor-Asurza, Cesar Augusto / Perich-Campos, Risto Alfredo / Alarcón, Graciela S / Ugarte-Gil, Manuel Francisco

Lupus science & medicine

2020 Volume 7, Issue 1, Page(s) e000366

Abstract: Introduction: Serum uric acid levels have been reported as predictors of cardiovascular, pulmonary, neurological and renal morbidity in patients with SLE. However, their role in cumulative global damage in these patients has not yet been determined.: ... ...

Abstract	Introduction: Serum uric acid levels have been reported as predictors of cardiovascular, pulmonary, neurological and renal morbidity in patients with SLE. However, their role in cumulative global damage in these patients has not yet been determined. Objective: To determine whether serum uric acid levels are associated with new damage in patients with SLE. Methods: This is a longitudinal study of patients with SLE from the Almenara Lupus Cohort, which began in 2012. At each visit, demographic and clinical characteristics were evaluated, such as activity (Systemic Lupus Erythematosus Disease Activity Index-2K or SLEDAI-2K) and cumulative damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index or SDI). Treatment (glucocorticoids, immunosuppressive drugs and antimalarials) was also recorded. Univariable and multivariable Cox regression models were used to determine the impact of serum uric acid levels on the risk of new damage. Results: We evaluated 237 patients, with a mean age (SD) at diagnosis of 35.9 (13.1) years; 220 patients (92.8%) were women, and the duration of the disease was 7.3 (6.6) years. The mean SLEDAI-2K and SDI scores were 5.1 (4.2) and 0.9 (1.3), respectively. Serum uric acid level was 4.5 (1.4) mg/dL. Follow-up time was 3.1 (1.3) years, and 112 (47.3%) patients accrued damage during follow-up. In univariable and multivariable analyses, serum uric acid levels were associated with new damage (HR=1.141 (95% CI 1.016 to 1.282), p=0.026; HR=1.189 (95% CI 1.025 to 1.378), p=0.022, respectively). Conclusion: Higher serum uric acid levels are associated with global damage in patients with SLE.
MeSH term(s)	Adult ; Antimalarials/adverse effects ; Antimalarials/therapeutic use ; Biomarkers/blood ; Comorbidity ; Disease Progression ; Female ; Follow-Up Studies ; Glucocorticoids/adverse effects ; Glucocorticoids/therapeutic use ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Longitudinal Studies ; Lupus Erythematosus, Systemic/blood ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/pathology ; Male ; Middle Aged ; Peru/epidemiology ; Severity of Illness Index ; Uric Acid/blood
Chemical Substances	Antimalarials ; Biomarkers ; Glucocorticoids ; Immunosuppressive Agents ; Uric Acid (268B43MJ25)
Language	English
Publishing date	2020-02-05
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2779620-6
ISSN	2053-8790
ISSN	2053-8790
DOI	10.1136/lupus-2019-000366
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Age at diagnosis and health-related quality of life are associated with fatigue in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.

Elera-Fitzcarrald, Claudia / Reátegui-Sokolova, Cristina / Gamboa-Cárdenas, Rocío V / Medina, Mariela / Zevallos, Francisco / Pimentel-Quiroz, Victor R / Zeña-Huancas, Paola A / Pastor-Asurza, César A / Perich-Campos, Risto A / Rodríguez-Bellido, Zoila J / Alarcón, Graciela S / Ugarte-Gil, Manuel F

Lupus

2020 Volume 29, Issue 12, Page(s) 1644–1649

Abstract: Objective: To define the factors associated with fatigue in Mestizo patients with Systemic Lupus Erythematosus (SLE).: Methods: This is a cross-sectional study of SLE patients from a single center cohort. Visits were performed every six months. For ... ...

Abstract	Objective: To define the factors associated with fatigue in Mestizo patients with Systemic Lupus Erythematosus (SLE). Methods: This is a cross-sectional study of SLE patients from a single center cohort. Visits were performed every six months. For these analyses, the first visit between October 2017 and December 2018 was included. Demographic and clinical characteristics as well as treatment were recorded at every visit. Fatigue was ascertained with the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-FT), Health-Related Quality of Life (HRQoL) with the LupusQoL, disease activity with the Systemic Lupus Erythematosus Disease Activity Index -2 K (SLEDAI-2K), and damage with the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology damage index (SDI). Prednisone use was recorded as current daily dose. Immunosuppressive drugs and antimalarial use were recorded as current, past or never. Univariable and multivariable analyses were performed using linear regression models. For the multivariable analyses, model selection followed a backward elimination procedure. Results: Two hundred and twenty-six patients were evaluated. The mean (SD) age at diagnosis was 35.6 (13.1) years, 211 (93.4%) were female; and disease duration was 11.0 (7.3) years. The mean SLEDAI and SDI were 2.4 (3.5) and 1.3 (1.5), respectively. The mean FACIT-FT was 33.1 (10.8). On the multivariable analysis, age at diagnosis and some domains of HRQoL (physical health, emotional health and fatigue) remained associated. Conclusions: Age at diagnosis is negatively associated with fatigue whereas HRQoL domains like physical health, emotional health and fatigue are positively associated with fatigue.
MeSH term(s)	Adult ; Age Factors ; Antimalarials/therapeutic use ; Cohort Studies ; Cross-Sectional Studies ; Ethnic Groups/psychology ; Fatigue/complications ; Fatigue/psychology ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Linear Models ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/ethnology ; Lupus Erythematosus, Systemic/psychology ; Male ; Middle Aged ; Multivariate Analysis ; Peru/ethnology ; Prednisone/therapeutic use ; Quality of Life/psychology ; Severity of Illness Index ; Sex Factors ; Surveys and Questionnaires ; Treatment Outcome ; Young Adult
Chemical Substances	Antimalarials ; Immunosuppressive Agents ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2020-08-02
Publishing country	England
Document type	Journal Article
ZDB-ID	1154407-7
ISSN	1477-0962 ; 0961-2033
ISSN (online)	1477-0962
ISSN	0961-2033
DOI	10.1177/0961203320947472
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3717: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Discrepant Perception of Lupus Disease Activity: A Comparison Between Patients' and Physicians' Disease Activity Scores.

Elera-Fitzcarrald, Claudia / Vega, Karen / Gamboa-Cárdenas, Rocío V / Zúñiga, Katiuska / Medina, Mariela / Pimentel-Quiroz, Victor / Pastor-Asurza, César / Perich-Campos, Risto / Rodríguez Bellido, Zoila / Griffin, Russell / Aranow, Cynthia / Alarcón, Graciela S / Calvo, Armando / Ugarte-Gil, Manuel F

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

2020 Volume 26, Issue 7S Suppl 2, Page(s) S165–S169

Abstract: Objective: The aim of this study was to compare patient and physician (MD) assessment of disease activity in systemic lupus erythematosus patients.: Methods: This cross-sectional study was conducted between August 2016 and December 2017 at 2 Peruvian ...

Abstract	Objective: The aim of this study was to compare patient and physician (MD) assessment of disease activity in systemic lupus erythematosus patients. Methods: This cross-sectional study was conducted between August 2016 and December 2017 at 2 Peruvian hospitals. One group assessed disease activity using a visual analog scale (VAS, 0-100 mm) and the other one using a numerical rating scale (NRS, 0-4), before and after their MD's visit. MDs assessed it with the Mexican Systemic Lupus Erythematosus Disease Activity (Mex-SLEDAI) (0-32) and with the SLICC/ACR Damage Index (SDI) for damage. Health-related quality of life was ascertained with the LupusQoL. Visual analog scale and NRS were compared using the Wilcoxon signed-rank test and the correlation between disease activity as assessed by the patient and the Mex-SLEDAI, SDI, and LupusQoL with the Spearman rank correlation. Results: Two hundred forty patients were included; mean (SD) age at diagnosis was 34.9 (12.9) years; most patients were Mestizo. Disease duration was 10.1 (7.0) years. The Mex-SLEDAI was 1.9 (2.7) and the SDI 1.2 (1.5). Disease activity as assessed by the patient, either by VAS or NRS, did not correlate with the Mex-SLEDAI or the SDI. In contrast, patient assessment of disease activity, by VAS or NRS, significantly correlated with several components of the LupusQoL (physical health, pain, planning, emotional health, and fatigue). Conclusions: Physician's and patient's assessments of disease activity are discrepant; overall, patients score higher than their MDs. Patients score how they perceive the disease is affecting them, rather than disease activity per se. The VAS could be more useful than the NRS as a measurement of disease activity.
MeSH term(s)	Cross-Sectional Studies ; Humans ; Lupus Erythematosus, Systemic/diagnosis ; Mexico/epidemiology ; Perception ; Physicians ; Quality of Life ; Severity of Illness Index
Language	English
Publishing date	2020-01-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	1283266-2
ISSN	1536-7355 ; 1076-1608
ISSN (online)	1536-7355
ISSN	1076-1608
DOI	10.1097/RHU.0000000000001267
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4815: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito